Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.
Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.
复制标题
DOI：
10.1007/s11897-017-0358-4
复制
发表时间：
2017-10-01
影响因子：
--
通讯作者：
DeVore, Adam D
中科院分区：
文献类型：
--
作者：
Cypen, Jeremy;Ahmad, Tariq;DeVore, Adam D
综述的目的：生物标志物在心力衰竭（HF）中的应用是一个快速变化的领域。本综述的目的是评估目前在保留射血分数（HFpEF）的心衰患者中使用生物标志物进行风险分层的证据。最新发现：尽管射血分数降低的HF与HFpEF在病理生理上存在差异，但传统的HF生物标志物，如脑利钠肽和肌钙蛋白，在大多数HFpEF特异性人群中仍具有预后价值。HFpEF关键病理生理成分的生物标志物，如心肌纤维化、重构和全身性炎症，也是有价值的预后标志物。对HF生物标志物的进一步研究可能会确定治疗HFpEF的重要治疗靶点。
PURPOSE OF REVIEW: The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF).RECENT FINDINGS: Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF.